1. Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients. Issue 1 (20th February 2019) Authors: Fässler, Mirjam; Diem, Stefan; Mangana, Joanna; Hasan Ali, Omar; Berner, Fiamma; Bomze, David; Ring, Sandra; Niederer, Rebekka; del Carmen Gil Cruz, Cristina; Pérez Shibayama, Christian Ivan; Krolik, Michal; Siano, Marco; Joerger, Markus; Recher, Mike; Risch, Lorenz; Güsewell, Sabine; Risch, Mart... Journal: Journal for immunotherapy of cancer Issue: Volume 7:Issue 1(2019) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. BRAF and MEK inhibition for the treatment of advanced BRAF mutant melanoma. (June 2015) Authors: Richman, Juliet; Martin-Liberal, Juan; Diem, Stefan; Larkin, James Journal: Expert opinion on pharmacotherapy Issue: Volume 16:Number 9(2015) Page Start: 1285 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. C reactive protein flare predicts response to checkpoint inhibitor treatment in non-small cell lung cancer. Issue 3 (15th March 2022) Authors: Klümper, Niklas; Saal, Jonas; Berner, Fiamma; Lichtensteiger, Christa; Wyss, Nina; Heine, Annkristin; Bauernfeind, Franz Georg; Ellinger, Jörg; Brossart, Peter; Diem, Stefan; Schmid, Sabine; Joerger, Markus; Frueh, Martin; Ritter, Manuel; Hölzel, Michael; Flatz, Lukas; Bald, Tobias Journal: Journal for immunotherapy of cancer Issue: Volume 10:Issue 3(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Characterization of nivolumab-associated skin reactions in patients with metastatic non-small cell lung cancer. (1st November 2016) Authors: Hasan Ali, Omar; Diem, Stefan; Markert, Eva; Jochum, Wolfram; Kerl, Katrin; French, Lars E.; Speiser, Daniel E.; Früh, Martin; Flatz, Lukas Journal: Oncoimmunology Issue: Volume 5:Number 11(2016) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Contrasting evidence to reimbursement reality for off-label use (OLU) of drug treatments in cancer care: rationale and design of the CEIT-OLU project. Issue 6 (1st December 2019) Authors: Herbrand, Amanda Katherina; Schmitt, Andreas Michael; Briel, Matthias; Diem, Stefan; Ewald, Hannah; Hoogkamer, Anouk; Joerger, Markus; Mc Cord, Kimberly Alba; Novak, Urban; Sricharoenchai, Sirintip; Hemkens, Lars G; Kasenda, Benjamin Journal: ESMO open Issue: Volume 4:Issue 6(2019) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Five-year review of corticosteroid duration and complications in the management of immune checkpoint inhibitor-related diarrhoea and colitis in advanced melanoma. Issue 4 (8th July 2020) Authors: Favara, David M; Spain, Lavinia; Au, Lewis; Clark, James; Daniels, Ella; Diem, Stefan; Chauhan, Dharmisha; Turajlic, Samra; Powell, Nick; Larkin, James M; Yousaf, Nadia Journal: ESMO open Issue: Volume 5:Issue 4(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors. (January 2019) Authors: Hasan Ali, Omar; Berner, Fiamma; Bomze, David; Fässler, Mirjam; Diem, Stefan; Cozzio, Antonio; Jörger, Markus; Früh, Martin; Driessen, Christoph; Lenz, Tobias L.; Flatz, Lukas Journal: European journal of cancer Issue: Volume 107(2019) Page Start: 8 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Management of toxicities of immune checkpoint inhibitors. (March 2016) Authors: Spain, Lavinia; Diem, Stefan; Larkin, James Journal: Cancer treatment reviews Issue: Volume 44(2016) Page Start: 51 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. (September 2017) Authors: Diem, Stefan; Schmid, Sabine; Krapf, Mirjam; Flatz, Lukas; Born, Diana; Jochum, Wolfram; Templeton, Arnoud J.; Früh, Martin Journal: Lung cancer Issue: Volume 111(2017) Page Start: 176 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Outcome of mantle cell lymphoma patients treated at a single institution over the past decade. Issue 4 (11th December 2013) Authors: Hitz, Felicitas; Diem, Stefan; Haile, Sarah R.; Ess, Silvia; Cerny, Thomas; Mey, Ulrich Journal: Hematological oncology Issue: Volume 32:Issue 4(2014:Dec.) Page Start: 192 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗